anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
For protocols which adopt a steroid prephase: patients who are Prednisone-good responder and achieve CR after the induction course. For protocols which do not adopt steroid prephase: patients who have M1/M2 BM at day 15 or M1 BM at day 21 and achieve CR after the induction course. Expected stratification in this group: 70-75%.
Tremor, defined as an "involuntary, rhythmic, oscillatory movement of a body part", is a key feature of many neurological conditions including Parkinson's disease and essential tremor. Clinical assessment continues to be performed by visual observation with quantification on clinical scales. Methodologies for objectively quantifying tremor are promising but remain non-standardized across centers. Our center performs full-body behavioral testing with 3D motion capture for clinical and research purposes in patients with Parkinson's disease, essential tremor, and other conditions. The objective of this study was to assess the ability of several candidate processing pipelines to identify the presence or absence of tremor in kinematic data from patients with confirmed movement disorders and compare them to expert ratings from movement disorders specialists. We curated a database of 2272 separate kinematic data recordings from our center, each of which was contemporaneously annotated as tremor present or absent by a movement physician. We compared the ability of six separate processing pipelines to recreate clinician ratings based on F1 score, in addition to accuracy, precision, and recall. The performance across algorithms was generally comparable. The average F1 score was 0.84±0.02 (mean ± SD; range 0.81-0.87). The second highest performing algorithm (cross-validated F1=0.87) was a hybrid that used engineered features adapted from an algorithm in longstanding clinical use with a modern Support Vector Machine classifier. Taken together, our results suggest the potential to update legacy clinical decision support systems to incorporate modern machine learning classifiers to create better-performing tools.
Compositions and methods for the treatment or prevention of Gram negative bacterial, such as  Salmonella spp.  infection, in a vertebrate subject are provided. The methods provide administering a composition to the vertebrate subject in an amount effective to reduce or eliminate the  Salmonella spp . bacterial infection and/or induce an immune response to the protein. Methods for the treatment or prevention of  Salmonella spp . infection in a vertebrate are also provided. Other compositions and methods are also disclosed.
Study 4 was a multicenter, randomized, 16-week, double-blind, placebo-controlled trial in 115 patients with histopathologically-confirmed neuroendocrine tumors and a history of carcinoid syndrome (flushing and/or diarrhea) who were treatment naïve or stable on another somatostatin analog and who were randomized 1:1 to receive lanreotide injection 120 mg (n=59) or placebo (n=56) by deep subcutaneous injection every 4 weeks. Patients were instructed to self-administer a short-acting somatostatin analog (octreotide) as rescue medication as needed for symptom control. The use of rescue therapy and the severity and frequency of diarrhea and flushing symptoms were reported daily in electronic patient diaries. During the 16 week double-blind phase, the primary efficacy outcome measure was the percentage of days in which patients administered at least one injection of rescue medication for symptom control. Average daily frequencies of diarrhea and flushing events were assessed secondarily.

The patient population had a mean age of 59 years (range 27 to 85 years), 58% were female and 77% were Caucasian. Patients in the lanreotide arm experienced 15% fewer days on rescue medication compared to patients in the placebo arm (34% vs. 49% of days, respectively; p=0.02). The average daily frequencies of diarrhea and flushing events in patients treated with lanreotide Injection (and rescue medication) were numerically lower relative to patients treated with placebo (and rescue medication), but were not statistically significantly different via hierarchical testing.
This is a randomized, double blind study with 2 treatment groups. Participants diagnosed with ADHF who meet the inclusion criteria and no exclusion criteria are given an explanation regarding the research and additional therapy that will be given, then informed consent is requested. Participants will be randomized to one of the two treatment groups by chance. Patients randomized to the first group will receive intravenous furosemide and oral acetazolamide. Patients randomized to the other treatment group will receive a combination of iv furosemide and placebo. It is expected that the patients of the treatment group with the combination therapy will have a faster reduction of their fluid overload. In consequence the treatment duration and total dose of diuretics administered will be shorter.
Treatment sequence ABECD is applied. The 5 treatments were separated by a washout period of at least 5 days.
α-Solanine has been shown to exhibit anti-inflammatory and anti-tumour properties; however, its efficacy in treating osteoarthritis (OA) remains ambiguous. The study aimed to evaluate the therapeutic effects of α-solanine on OA development in a mouse OA model. The OA mice were subjected to varying concentrations of α-solanine, and various assessments were implemented to assess OA progression. We found that α-solanine significantly reduced osteophyte formation, subchondral sclerosis and OARSI score. And it decreased proteoglycan loss and calcification in articular cartilage. Specifically, α-solanine inhibited extracellular matrix degradation by downregulating collagen 10, matrix metalloproteinase 3 and 13, and upregulating collagen 2. Importantly, α-solanine reversed chondrocyte pyroptosis phenotype in articular cartilage of OA mice by inhibiting the elevated expressions of Caspase-1, Gsdmd and IL-1β, while also mitigating aberrant angiogenesis and sensory innervation in subchondral bone. Mechanistically, α-solanine notably hindered the early stages of OA progression by reducing I-κB phosphorylation and nuclear translocation of p65, thereby inactivating NF-κB signalling. Our findings demonstrate the capability of α-solanine to disrupt chondrocyte pyroptosis and sensory innervation, thereby improving osteoarthritic pathological progress by inhibiting NF-κB signalling. These results suggest that α-solanine could serve as a promising therapeutic agent for OA treatment.
Dietary lipids play an essential role in regulating the function of the gut microbiota and gastrointestinal tract, and these luminal interactions contribute to mediating host metabolism. Palmitic Acid Hydroxy Stearic Acids (PAHSAs) are a family of lipids with antidiabetic and anti-inflammatory properties, but whether the gut microbiota contributes to their beneficial effects on host metabolism is unknown. Here, we report that treating chow-fed female and male germ-free (GF) mice with PAHSAs improves glucose tolerance, but these effects are lost upon high fat diet (HFD) feeding. However, transfer of feces from PAHSA-treated, but not vehicle-treated, chow-fed conventional mice increases insulin sensitivity in HFD-fed GF mice. Thus, the gut microbiota is necessary for, and can transmit, the insulin-sensitizing effects of PAHSAs in HFD-fed GF male mice. Analyses of the cecal metagenome and lipidome of PAHSA-treated mice identified multiple lipid species that associate with the gut commensal Bacteroides thetaiotaomicron (Bt) and with insulin sensitivity resulting from PAHSA treatment. Supplementing live, and to some degree, heat-killed Bt to HFD-fed female mice prevented weight gain, reduced adiposity, improved glucose tolerance, fortified the colonic mucus barrier and reduced systemic inflammation compared to HFD-fed controls. These effects were not observed in HFD-fed male mice. Furthermore, ovariectomy partially reversed the beneficial Bt effects on host metabolism, indicating a role for sex hormones in mediating the Bt probiotic effects. Altogether, these studies highlight the fact that PAHSAs can modulate the gut microbiota and that the microbiota is necessary for the beneficial metabolic effects of PAHSAs in HFD-fed mice.
The present invention provides antibodies that bind with high affinity and specificity to CD47, and their use in the treatment of cancer. In one example of the invention, an antibody or antigen-binding fragment thereof blocks the interaction of CD47 with signal-regulated protein alpha (SIRP-alpha). In another aspect, the invention provides CD47 antibodies that are reformatted to IgG 4. In yet another aspect, the present invention provides a method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of an anti-CD 47 antibody. In a further aspect, the invention provides a pharmaceutical composition comprising a therapeutically acceptable amount of an anti-CD 47 antibody and one or more pharmaceutically acceptable carriers. In particular, the pharmaceutical composition is effective in treating cancer.
Structural changes to the vocal fold (VF) epithelium, namely, loosened intercellular junctions, have been reported in VF benign lesions. The potential mechanisms responsible for the disruption of cell junctions do not address the contribution of resident microbial communities to this pathological phenomenon. In this study, we focused on determining the relationship between Streptococcus pseudopneumoniae (SP), a dominant bacterial species associated with benign lesions, and Streptococcus salivarius (SS), a commensal bacterium, with human VF epithelial cells in our three-dimensional model of the human VF mucosa. This experimental system enabled direct deposition of bacteria onto constructs at the air/liquid interface, allowing for the assessment of bacterium-host interactions at the cellular, molecular and ultrastructural levels. Our findings demonstrate that SP disrupts VF epithelial integrity and initiates inflammation via the exported products HtrA1 and pneumolysin. In contrast, SS attaches to the VF epithelium, reduces inflammation and induces Mmp2-mediated apical desquamation of infected cells to mitigate the impact of pathogens. In conclusion, this study highlights the complexity of microbial involvement in VF pathology and potential VF mucosal restoration in the presence of laryngeal commensals.
All of the participants of the experimental group will be treated with ventilator hyperinflation technique (VHI) for 3 days. Tidal volume will increase from baseline (100% VT) to the tidal volume target at 1.5 times (150% VT). At this level, patients will receive six breathes and in each breathe will be sustained for 5 second (6 hyperinflation breathe per set); expiratory VT will return to baseline after each breath. Four sets of hyperinflation breathing will be used. After this, VT will decrease to baseline and patients have a 60 second for rest between hyperinflation set. The ventilator hyperinflation technique (VHI) consists of three consecutive periods; (1) baseline period: 10 minutes, (2) intervention period, and (3) recovery period: 10 minutes.
Preterm birth is the number one cause of infant morbidity and mortality worldwide and represents an important health disparity in the United States, and especially across the state of Kentucky. The best biomarker for the prediction of preterm birth is transvaginal ultrasound (TVU) measurement of cervical length. However, several unique provider and patient related barriers for implementation of this screening limit the widespread uptake of this evidence based practice in Appalachian KY. The investigators propose to adopt a dissemination and implementation science approach using the Consolidated Framework for Implementation Research (CFIR) as the guiding framework for identification of key areas of knowledge deficits as well as attitudes, practices and perceived barriers among prenatal care providers and patients in eastern KY towards TVU cervical length screening using a mixed - methods design. This will be utilized to develop a multifaceted implementation strategy best suited for addressing and overcoming barriers identified by the target population in eastern KY. The investigators anticipate that such an implementation strategy will likely include an educational component targeting obstetric care providers and patients in addition to hands-on TVU cervical length evaluation as well as telemedicine support and surveillance. Three community based sites (Hazard, Morehead and Ashland, KY) will be recruited for implementation of this multi-component pilot program focused on community engagement and outreach targeting obstetric providers and their patients. At the end of the pilot implementation phase, acceptability of the study intervention and feasibility of implementation will be evaluated along with a preliminary assessment of effectiveness of implementation.
The present invention discloses a drug for treating diabetic nephropathy. The drug is prepared in a mode that 11 kinds of traditional Chinese medicinal materials of astragalus root, Fructus Corni, rehmanniae, wine rhubarb, kudzu root, Rhizoma Alismatis, red sage root, motherwort, peach kernel, Radix Pseudostellariae and wolfberry fruit are used as raw materials. The present invention also discloses a preparation method of the drug, and the drug of the present invention has the effects of nourishing the liver and the kidney, benefiting qi, nourishing yin, expelling blood stasis, dredging collaterals, inducing diuresis and removing edema and mainly treats diabetic nephropathy. The pathological symptoms of dim complexion, tiredness, weakness, shortness of breath, unwillingness to speak, spontaneous sweat or night sweat, thirst, desire for drinking, dysphoria with feverish sensation in chest, palms and soles, dry and hard feces, dark tongue quality or petechia and ecchymosis, dark purple sublingual bluish tendons, the engorgement of the sublingual bluish tendons and fine and astringent veins appear. The persons with the pathological symptoms belong to persons which have deficiency of both qi and yin and venation stasis. The present invention has the quick action on the deficiency of both vital energy and yin of diabetic nephropathy and a symptom of the insufficiency of the liver and the kidney with a blood stasis symptom and has the advantages of obvious effect and no adverse reaction.
Despite the enrichment of VA suicide prevention services and implementation of the national suicide hotline, Veteran suicide completions have risen to 22 per day and suicide attempts numbered over 15,000 in 2012. These data underscore the urgency of developing additional interventions targeting suicidal Veterans. The construction of a Suicide Safety Plan (SSP); a "best practice", is mandated throughout the VA system, and a vital component of the VA's coordinated effort at suicide prevention and recovery. The investigators' pilot data on patterns of SSP use in suicidal Veterans over a 30 day time frame demonstrates that only 65% of Veterans used their safety plans, coping strategies listed on the plan were often mismatched or inadequate to the individual's needs, and limited access to the SSP during times of stress negatively impacted its utility. To the investigators' knowledge, there are currently no recommended guidelines or mechanisms for refinement of the SSP in adult populations beyond its initial development. "Project Life Force" (PLF), a novel suicide safety planning group intervention has been designed to fill this critical gap and provide a mechanism to develop and enhance suicide safety planning over time. PLF, a 12-session, group psychotherapy intervention, combines Dialectical Behavioral Therapy (DBT) skill based and psychoeducational approaches, to enhance suicide safety planning development and implementation. Veterans revise their plans over several weeks while learning distress tolerance, emotion regulation, and friendship building/interpersonal skills to incorporate into their safety plans and also receive lessons on gun safety and minimizing access to lethal means. Sessions are augmented with 1) training in the use of a suicide safety planning mobile App to promote accessibility and maximize implementation, and 2) didactic information to bolster recovery, including fostering improved connection with the treatment team, and Veteran's family. Importantly, the group format mitigates loneliness and fosters increased "belongingness", both key risk factors for suicide. Additionally, PLF's weekly format facilitates VA-mandated monitoring for any Veteran placed on the suicide "high risk" list.

Data from this project will test the intervention's feasibility, acceptability and preliminary efficacy and provide pilot data for a larger randomized clinical trial. The project is comprised of two phases. In Phase 1, the investigators will finalize the PLF intervention and accompanying manual and handouts. In Phase 2, the investigators will conduct an open label trial of PLF in 50 suicidal Veterans to evaluate the feasibility and acceptability of the intervention. The investigators will also test whether PLF affects outcomes of suicide ideation, depression, hopelessness, and outpatient compliance by examining clinically meaningful differences in these measures before and after PLF.
A method is performed in a health study management system for collecting health-related data from user devices associated with participants in a health study. The health-related data may include: data indicative of user health, and source data from which data indicative of user health can be derived. The method includes receiving a health study configuration specifying data collection activities for a health study and scheduling information for the data collection activities. For each study participant, a data collection configuration is generated including schedule data based on the health study configuration for a user device associated with the study participant. The schedule data defines a schedule of data collection activities performed at the user device, each data collection activity obtaining respective health-related data for the study participant. The data collection configuration generated is transmitted to each user device to configure data collection activities to be performed at the user device.
The medicament is produced by boiling the fresh, whole plant to dryness in a fatty edible prod. (pref. fresh cream, table oil or lard). Pref, boiling is for 1-1 1/2 hrs. and the wt. ratio of cream to the plant is 2 : 1. The medicament may also be taken orally for the treatment of inflammation and ulceration of the gastric mucous membrane.
PURPOSE:To obtain the titled cosmetic capable of improving the nutrition of hair root cells by effect on increase in oxygen supply to the interior of the body and preventing the depilation, dandruff, etc., by incorporating germanium collected or extracted from a plant, e.g. a polypore or ginseng, etc. with other components. CONSTITUTION:Germanium collected or extracted from a plant, e.g. polypore, ginseng, hydrangea, comfrey or lycii fructus, is incorporated with other components. The organic germanium in the plant in the form of a liquid or cream is characterized in that it is capable of supplying oxygen to the skin, improving the nutritional state of the skin and promoting the hair production of the skin, and promoting the hair growth and production by sufficient supply of oxygen to cells in the hair root sites. The cosmetic is effective for preventing the depilation, dandruff, itching, gray hair, etc., and improving beauty culture.
BACKGROUND: Erythropoiesis-stimulating agents (ESAs) have played an important role in the treatment of renal anemia in children, but cannot improve hemoglobin to target level in some cases. Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, can stimulate endogenous erythropoietin production and regulate iron metabolism even in patients with kidney failure. However, roxadustat has not yet been approved for use in children.
CASE-DIAGNOSIS/TREATMENT: We report a case of refractory renal anemia in an 80-day-old boy, who was hyporesponsive to ESAs even in combination with iron supplementation and transfusion. Compassionate use of roxadustat successfully corrected the intractable anemia. Hyperkalemia is a manageable adverse event of concern during follow-up.
CONCLUSION: The successful experience in this case may inform the clinical utility of roxadustat for refractory renal anemia in children, which should be further confirmed by well-designed prospective clinical trials.
PURPOSE:To produce a functional food capable of suppressing sharp taste by gelatinizing a mixture solution of an alkaline aqueous solution of a phenolic sharp taste ingredient with an aqueous solution of a natural paste with polyvalent metal ions. CONSTITUTION:A phenolic sharp taste ingredient is dissolved in, e.g. an aqueous solution of sodium or potassium. A natural paste, e.g. gum arabic, agar or alginic acid capable of dissolving or dispersing in water, producing consistency and gelling with metallic ions is converted into an aqueous solution and both the aqueous solutions are homogeneously mixed. The resultant mixture solution is then dripped into an aqueous solution of physiologically acceptable polyvalent metallic ions into a spherical or fibrous shape. For example, an aqueous solution of a mineral acid salt or an organic acid salt of Ca<2+> or Fe<2+> is used as the polyvalent metallic ions. The produced get is subsequently collected by filtration, etc. The collected gel is then heated and hardened in the aqueous solution of the polyvalent metallic ions and subsequently washed with warm water to produce the aforementioned gel.
PURPOSE: To use each of derivs. of 6,6-dimethyl-2-acylcyclohex-4-en-1,3-dione including a new deriv. as an effective component of anti-suntan cosmetics especially effective to UV-A. CONSTITUTION: Each of derivs. of 6,6-dimethyl-2-acylcyclohex-4-en-1,3-dione represented by formula I (R1 is 1-6C alkyl, R2 is H or 1-6C alkyl, R3 is H, OH or 1-6C alkoxy) is used as an anti-suntan agent. Among the derivs., 4,6,6- trimethyl-5-methoxy-2-acetylcyclohex-4-en-1,3-dione represented by formula II is new. It is obtd. by adjusting the pH of a soln. of alkali enolate of 4,6,6- trimethyl-5-methoxy-2-acetylcyclohex-4-en-1,3-dione so that the corresponding enol is liberated and then extracting and isolating the enol with solvent.
BACKGROUND: Although serum bicarbonate is a reliable predictor of various disease complications, its relationship with postoperative delirium (POD) remains unclear. Our research aimed to assess the effect of baseline serum bicarbonate levels on the incidence of POD in cardiac surgery patients.
METHODS: A retrospective analysis was conducted on cardiac surgery patients who met specific inclusion and exclusion criteria, using data from the Marketplace for Information in Critical Care Medicine (MIMIC-IV) database. Univariate and multivariate logistic regression models are employed to explore the correlation between serum bicarbonate levels and the risk of POD, and their predictive efficacy is assessed by means of restricted cubic spline regression models (RCS) and receiver operating characteristic curves (ROC). In addition, subgroup and sensitivity analyses are conducted to test the robustness of the results.
RESULTS: In this study, 5,422 patients were included, where the incidence of POD was 13.0%. For each 1 mmol/L increase in bicarbonate, a 13% reduction in the risk of POD was observed in the fully adjusted model (OR = 0.87, 95% CI: 0.83-0.91, P < 0.001). The RCS model demonstrated a linear negative correlation between the level of bicarbonate and the risk of POD (P for nonlinearity = 0.987). The ROC curve analysis demonstrated that the bicarbonate level had moderate predictive efficacy (AUC = 0.629). Both subgroup and sensitivity analyses reaffirmed the robustness of these results.
CONCLUSIONS: Lower baseline serum bicarbonate levels in cardiac surgery patients are linked to a higher risk of POD. Monitoring and adjusting serum bicarbonate levels may help identify high-risk patients and potentially improve outcomes.